Woodline Partners LP Arcus Biosciences, Inc. Transaction History

Woodline Partners LP

$13.5 Billion
Q4 2024

A detailed history of Woodline Partners LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 3,523,937 shares of RCUS stock, worth $37.8 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

3,523,937

Previous 3,478,440 1.31%

Holding current value

$37.8 Million

Previous $53.2 Million 1.34%

% of portfolio

0.39%

Previous 0.48%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$14.28 - $18.44 $649,697 - $838,964	45,497 Added 1.31%	3,523,937 $52.5 Million
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $10.5 Million - $13.8 Million	-766,781 Reduced 18.06%	3,478,440 $53.2 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $19.9 Million - $25.2 Million	1,361,564 Added 47.22%	4,245,221 $64.7 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $27.4 Million - $37.3 Million	1,846,375 Added 178.0%	2,883,657 $54.4 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $13.9 Million - $18.6 Million	789,282 Added 318.26%	1,037,282 $18.6 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $4.21 Million - $5.46 Million	248,000 New	248,000 $5.04 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $23.7 Million - $42.9 Million	1,201,150 New	1,201,150 $24.8 Million
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $4.5 Million - $9.86 Million	-261,419 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $41.8 Million - $60.4 Million	-1,445,006 Reduced 84.68%	261,419 $8.25 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $229,450 - $354,412	7,312 Added 0.43%	1,706,425 $69.1 Million
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $957,226 - $1.34 Million	35,545 Added 2.14%	1,699,113 $59.2 Million
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $9.69 Million - $15.2 Million	425,838 Added 34.4%	1,663,568 $45.7 Million
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $32.4 Million - $51.2 Million	1,237,730 New	1,237,730 $34.8 Million
Q2 2020 Aug 14, 2020	SELL	$13.97 - $36.56 $1.38 Million - $3.6 Million	-98,516 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $864,970 - $1.9 Million	98,516 New	98,516 $1.37 Million

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $775M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Arcus Biosciences, Inc. Transaction History